Page 760 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

744 Index

Anemia o in ammation (AOI) bone marrow destruction, 246–247, 247 in ammatory mediators synthesis, 180
characteristics, 265 hematopoietic ailure, 246–247 maturation, 165, 165

etiology, 265 immune mediated, 245 maturational characteristics, 165, 166, 166–169,
laboratory characteristics, 267–268 immune system and hematopoietic cells, 246 167t
clinical chemistry, 268 laboratory studies, 246 mature orms, 168
hematology, 267–268 phases, 246t production, 164–165

mechanisms, 265t treatment, 247 BCR-ABL1 usion gene, 452
pathophysiology, 265–267 Apoptosis, 105, 417 Beckman-Coulter, 625–626, 626b
treatment, 268–270 anticancer treatment, cytotoxic drugs, 70 Bernard–Soulier syndrome (BSS), 520
Anemias, MCV and RDW, 629, 629t autoimmune disorders, 70 Beta globin locus, 126

Aneuploidy, 375, 432 in hematopoietic and lymphoid systems, 69 Beta-thalassemia, 131
Angiogenesis, 418 intrinsic and extrinsic, 69 Betke method, 689, 689
Anion exchanger protein, 113 leukemias, 70 Bilirubin
Anisochromia, 149 prevention o , 69 conjugated, 132

Anisocytosis, 142, 142, 220 regulatory stimuli, 69–70 unconjugated, 132
Ankyrin, 113 vs. necrosis, 68, 69t Bimodal cellular distribution, 627
Antibodies, 189, 439–440 aP (see Activated partial thromboplastin time) Binucleated lymphocytes, 196
Antibody-dependent cellular cytotoxicity (ADCC), Argatroban, 575 Biohazard, 6

198–199 Arthrocentesis, 605 Biohazard symbol, 5, 10
Anticoagulant therapy Arti acts, 608 Bite cells, 145, 146
argatroban, 575 Arti cial neural networks (ANNs), 638 Blasts, 382
ondaparinux (arixtra), 575 Ascites, 596, 599 Bleeding disorders related to blood clotting

heparin, 575 ASO-PCR (see Allele-speci c oligonucleotide PCR coagulation actor assays, 557–559, 557t
lepirudin, 575 (ASO-PCR)) de ective production
low molecular weight heparin (LMWH), 575 Atrophy, 61, 61 hereditary clotting de ects, 553–556, 553t,
new oral anticoagulants (NOAs), 575–577, Atypical chronic myeloid leukemia (aCML), 458, 554t, 556t

576t, 577t 458t, 484 severe liver disease, 551
war arin, 574 Atypical hemolytic uremic syndrome (aHUS), 294 vitamin K de ciency, 551
Anticoagulants, 537 Auer rods, 166, 167, 390 X-linked disorders o secondary hemostasis,
dipotassium ethylenediaminetetraacetate Autoimmune hemolytic anemia, 516 551–553, 552, 553t

(K ED A), 28 cold-type, 302 destruction and consumption disorders
2
evacuated blood tubes, 34t drug-induced, 302b disseminated intravascular coagulation,
heparin, 28 isoimmune, 302b 559–563, 562b, 562t, 563t
sodium citrate, 28 microorganisms, 302t brinolysis, 559, 560t

stopper colors, 34t warm- and cold-type, 302, 303t elevated brin split products, 563
tripotassium ethylenediaminetetraacetate warm-type, 302 Bleeding time
(K ED A), 28 Autoimmune hemolytic anemias (AIHA), standardized IVY method, 695
3
Antigens, 189 301–302 with and without aspirin, 499–500

Antineutrophil cytoplasmic antibody-positive Autoimmune lymphoproli erative syndrome Blister cells, 145–146, 146
vasculitis (ANCA), 506 (ALPS), 190 Blood-brain barrier, 585
Antiphospholipid antibodies, 568–569 Azurophilic granules, 98, 166, 390 Blood clotting actors, hypercoagulable state,
Antiphospholipid syndrome (APS), 559, 569–570 566–567

Antiplatelet agents B Blood coagulation actors
aspirin, 498 B-cell prolymphocytic leukemias (B-PLLs), 422 basic concepts o , 527, 527t
clopidogrel, 498 B cells cell-based coagulation
dipyridamole, 498 a nity maturation, 201 ampli cation phase, 532, 532

GP IIb/IIIa antagonist, 498–499 anatomical origin, 189 implications, 533
prasugrel, 498 antibody-independent roles, 201 initiation phase, 532, 532
ticagrelor, 799 characteristics, 198 propagation phase, 532, 532
Antiplatelet antibody assays, 500 development sites stabilization phase, 532, 532–533

Antithrombin (A ), 541, 561 primary lymphoid tissue, 189, 189 characteristics o , 527–528, 528t
Antithrombin III de ciency, 573 secondary lymphoid tissue, 189–190, complement system, 534
Anuclear characteristics, thrombocytes and eryth- 190–191 actor I ( brinogen), 528
rocytes, 96 immunological characteristics, 201 actor II (prothrombin), 528

Anuclear mature cell, 107 maturation, 199, 203 actor IIa (thrombin), 528
AOI (see Anemia o in ammation) monoclonal antibodies, 199–200 actor III (tissue thromboplastin), 528
Aplastic anemia plasma cell development and maturation, 202, actor IV (ionized calcium), 528–529
clinical eatures, 246 202–204, 203 actor IX (plasma thromboplastin component),

constitutional bone marrow ailure syndromes B lymphocytes, 189, 189t, 191, 198, 202 529
Diamond-Black an anemia (DBA), 250 Babesiosis, 156–157 actor V (proaccelerin), 529
dyskeratosis congenita, 249 Bacteremia, 179 actor VII (proconvertin), 529
erythroblastopenia, 249 Band 3 (see Anion exchanger protein) actor VIII (antihemophilic actor), 529

Fanconi anemia, 248–249 Basic calcium phosphate (BCP) crystals, 606 actor X (stuart actor), 529
pure red cell aplasia (PRCA), 249–250 Basic lymphocyte screening panel, 636 actor XI (plasma thromboplastin antecedent),
telomeres, 251 Basilic vein, 39 529
description, 244 Basophil/lobularity (nuclear) channel, 633, 633 actor XII (hageman actor), 529

etiology Basophilic erythrocyte, 149–150 actor XIII ( brin-stabilizing actor), 530
benzene, 244–245 Basophilic granules, 98 brin ormation assays
classi cation, 245b Basophilic normoblast, 107 (see also D-dimer testing, 538–539, 539
constitutional, 244 Prorubricyte) brinogen levels, 538

drugs, 245 Basophilic stippling, 150, 151 reptilase time, 538
in ections, 245 Basophils thrombin time, 538
ionizing radiation, 244 assessment methods, 249, 217 brinolysis, 533–534, 533b
laboratory ndings, 246–247 development, 165, 165 global testing, 539–540, 540

pathophysiology distribution, 165–166 International normalized ratio, 535
blood cell destruction, 247 granulation, 168–169 kinin system, 534